reports
- Guy Sips
Amoéba Presenting the 2025 results of its vineyard trial campaign
We welcome AXPERA confirms its effectiveness against downy mildew and its strong potential to significantly reduce copper use. These field trials were confirming AXPERA's strong performance in real conditions. Amoéba presented nice results of its 2025 vineyard trial campaign confirming AXPERA's effectiveness against downy mildew, as observed in previous years — and particularly in 2024, a season during which the disease proved especially virulent. The results obtained in 2025 confirm that the in...
- Guy Sips
Amoéba Obtaining market authorisation in US for its AXPERA biocontrol ...
We welcome Amoéba's first two biocontrol fungicides, AXPERA NOA and AXPERA GREEN, received approval from the US Environmental Protection Agency (US EPA) for the first crops targeted by Amoéba. Amoéba also indicated it is progressing in line with its strategic plan to begin marketing its biocontrol solution in Europe and the US in 2026. Amoéba announced that it has received regulatory approval from the US Environmental Protection Agency (EPA) to market in the US its biocontrol products AXPERA N...
- Guy Sips
Amoéba Setting up Green 4 Agro, structuring its activities in biocontr...
Amoéba takes a further step in the structuring of its activities in the area of biocontrol, confirming its ambition to become a key player in the agroecological transition by setting up Green 4 Agro, its subsidiary dedicated to the commercialisation and development of its biocontrol and biostimulant solutions. As a reminder, commercial operations will begin in 2026 with the distribution of its AXPERA biocontrol solution for vineyards and vegetable crops, through its first partner, Koppert. Green...
- Guy Sips
Amoéba Now full speed ahead to commercial launch of its biocontrol sol...
First-half result numbers overshadowed by the various milestones achieved over the past two years by its biocontrol solution (with final approval of the active substance by the European Commission and the signing of a strategic distribution agreement with Koppert) now enables them to launch its commercialisation in 2026. The US EPA (Environmental Protection Agency) decision on the application for federal marketing authorisation in the US for AXPERA, which has been delayed for reasons beyond Amoé...
- Guy Sips
Amoéba Very convincing results observed by winegrowers
Amoéba announced positive results of its wine-growing trials in France and Europe. Amoéba conducted a series of trials with winegrowers in several major French wine-growing regions. The main objectives of this campaign were to demonstrate the effectiveness of AXPERA, its innovative biological solution, and to validate its reliability in local programmes and practical conditions. We saw results incorporating AXPERA into vineyards' treatment programme that has enabled them to reduce copper input w...
- Guy Sips
Amoéba Capital increase to support its industrial and commercial rollo...
We updated our model (new € 1.5 Target Price, Buy) after Amoéba announced the closure of its capital increase to support its industrial and commercial rollout. Amoeba has therefore raised a gross amount of €14m, including €9m in cash contributed by institutional and individual investors, and €5m by offsetting receivables bringing the number of shares to 68.9m. Amoéba indicated they now have sufficient financial resources to support its industrial and commercial growth and create value for its ...
- Thomas Vranken
Amoéba Exemption from obligation to destroy trial crops in France
The French regulator ANSES has granted an exemption for Amoéba's biocontrol product Axpera, allowing crop trials without the usual requirement to destroy the harvest. This exemption, which applies to both open-field and greenhouse crops affected by various diseases, supports ongoing evaluations and follows recent regulatory milestones in France and the EU. While no material commercial sales are expected yet in 2025, the move is seen as another strong endorsement of Amoéba's innovative technology...
- Thomas Vranken
Amoéba EU approval for Axpera's active substance
Amoéba has received final approval from the European Commission for the active substance of its biocontrol product, Axpera, marking it as a low-risk substance. This milestone concludes a five-year EU validation process and positions the company for commercialisation in Europe, with marketing authorisation applications underway in nine countries and decisions expected by late 2025/early 2026. We maintain a Buy rating with € 1.8 TP.
- Thomas Vranken
Amoéba Partnership with Koppert signed
Amoéba has finalized a major five-year distribution agreement with Dutch biocontrol leader Koppert for its biofungicide Axpera, following a memorandum of understanding signed in December 2024. The deal grants Koppert exclusive rights across 18 European countries and the US, with a product launch expected in early 2026 under Koppert's brand. Production will occur at Amoéba's Chassieu site and via CDMO partners. The companies also plan to co-develop new biofungicide solutions. While financial term...
- Thomas Vranken
Amoéba Unanimously positive EU vote on active substance as biocontrol
Amoéba received unanimous positive votes from all 27 EU Member States for its active substance to be used as a low-risk biocontrol. The vote followed a positive scientific opinion from EFSA in January 2025 and now paves the way for the European Commission to formalize the approval through an implementing regulation. The vote supports Amoéba's plans to commercialize its biocontrol product Axpera, with first EU sales expected by late 2025 or 2026, as the final product is already undergoing regulat...
- Thomas Vranken
Amoéba Talks with Koppert extended
Amoéba announced that it continues its discussions with Dutch biocontrol leader Koppert to prepare for the commercial launch of Amoéba's biocontrol product Axpera. Initiated in December 2024, these talks have been extended to finalize contractual documentation following constructive discussions on market expectations and commercial strategies. Meanwhile, Axpera has received emergency market authorization in France for combating downy mildew in vines and exceptional authorization for use in sever...
- Thomas Vranken
Amoéba Authorisation for large-scale greenhouse trials in the Netherla...
Amoéba has received an exceptional exemption in the Netherlands for large-scale greenhouse trials with its biocontrol product, Axpera, allowing the crops to be consumed. The authorisation could help validate Axpera's effectiveness under commercial conditions and potentially speed up the commercial rollout once formal EU approval has been obtained. We see strong potential in Amoéba's amoeba lysate in both biocontrol and cosmetics, hence reiterate our Buy rating with a € 1.7 TP.
- Thomas Vranken
Amoéba Axpera obtains emergency market authorisation in France
Amoéba has received a 120-day emergency market authorisation from the French Ministry of Agriculture for its biocontrol product Axpera to combat downy mildew on grapevines in France. This approval allows large-scale field trials from mid-April to mid-August 2025, covering up to 250 hectares, supported by the French Wine and Vine Institute. The milestone represents another validation of Amoéba's innovative biocontrol application, and while significant sales are not yet expected in 2025, the early...
- Guy Sips
- Thomas Vranken
Amoéba An amoebalicious adventure from fungus fighters to wrinkle warr...
We initiate coverage on Amoéba, an industrial biotechnology company based in Chassieu, France, that focuses on innovative uses of the amoeba Willaertia magna C2c Maky. The company aims to become a major player in the global biocontrol market for plant protection as well as the cosmetics market. Based on a DCF/SOTP analysis, we issue a € 1.7 TP and Buy rating.
Edison issues report on Amoéba (ALMIB)
Edison Investment Research Limited Edison issues report on Amoéba (ALMIB) 21-Jun-2024 / 12:36 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 21 Juni 2024 Edison issues report on Amoéba (ALMIB) to view the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the . Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, p...
- Toby Thorrington
Amoeba - Focused on high-value opportunities
Amoéba has achieved promising results for the use of its amoeba-based active ingredient in skincare cosmetics in a series of lab and human volunteer trials. In addition, the company secured regulatory approval in the United States and a recommendation for approval in the European Union in 2022 for the active ingredient used in its innovative biological fungicides. Since then, it has tested this active ingredient in standalone and blended use and hopes to achieve product approvals by H125. Amoéba...
- Toby Thorrington
Amoeba - Biocontrol plant paves path to commercialisation
Thus far, FY23 has marked a year of successful advancement for Amoéba: (1) the development of its biocontrol plant is ongoing, poised to achieve production of 40 tonnes per annum of W. magna lysate; (2) a third scientific article has been published, which highlights the efficacy of its biocontrol product; and (3) the company has announced a potential further application for W. magna lysate in cosmetic skincare. The new application will not hinder advancement of the biological fungicide product. ...
- Arnaud Despre
- Augustin Socié
- Clément Bassat
- Gaetan Calabro
- Jeremy Sallee
- Maxence Dhoury
- Mohamed Kaabouni
- Nicolas Delmas
- Nicolas Royot
La Matinale - 22-06-2023
LA VALEUR DU JOUR : ACTIA GROUP : Feedback Conférence Portzamparc – Conserver (3), obj. 4.70€ Cours: 4.67€ au 21/06/23 AFYREN : Feedback Conférence Portzamparc – Acheter (1), obj. 9.40€ Cours: 5.70€ au 21/06/23 AMOEBA : Feedback Conférence Portzamparc – Acheter (1), obj. 0.72€ Cours: 0.58€ au 21/06/23 BENETEAU : Feedback Conférence Portzamparc – Acheter (1), obj. 23.0€ Cours: 15.3€ au 21/06/23 EXAIL TECHNOLOGIES : Feedback Conférence Portzamparc – Acheter (1), obj. 26.5€ Cours: 20.2€ au 21/...
ALHRG HERIGE
EXE EXEL INDUSTRIES SA
BEN BENETEAU SA
ALPJT POUJOULAT
METEX METABOLIC EXPLORER SA
MTU MANITOU BF SA
LNA LNA SANTE SA
GOE GROUPE GORGE SA
NANO NANOBIOTIX SA
ATI ACTIA GROUP
MCPHY MCPHY ENERGY SA
MITRA N.V. MITHRA PHARMACEUTICALS S.A.
AMEBA AMOEBA SA
SPIE SPIE SA
PWG PRODWAYS GROUP SA
TXG 10X GENOMICS INC CLASS A
ALLGO LARGO
ALAFY AFYREN
WAGA WAGA ENERGY SA
LHYFE LHYFE S.A.
- Toby Thorrington
Amoeba - Scaling up for commercialisation
Following on from the press release in March that provided preliminary data on the FY22 results, Amoéba has published its FY22 universal registration document, which contains detailed financial information for the year. We leave our FY23 estimates unchanged.
- Mohamed Kaabouni
NOTE - Amoeba - Strong Buy - Initiation of Coverage - TP: €0.72
Amoéba is a cleantech company committed to the ecological transition through two main applications, the objective of which is to reduce the use of chemical products that are devastating for the environment and health. Amoéba's technology is based on the amoeba Willaertia magna, a type of micro-organism that is still little exploited, unlike bacteria, which are essential for wastewater treatment, or yeast. We initiate coverage of Amoéba with a Strong Buy (1) recommendation and a target price of €...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.